<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OPSUMIT- macitentan tablet, film coated </strong><br>Actelion Pharmaceuticals US, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use OPSUMIT safely and effectively. See full prescribing information for OPSUMIT.<br><br> OPSUMIT<span class="Sup">®</span> (macitentan) tablets, for oral use<br> Initial U.S. Approval: 2013</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING:  EMBRYO-FETAL TOXICITY</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning</span></h1>
<ul class="Disc">
<li><span class="Bold">Do not administer OPSUMIT to a pregnant female because it may cause fetal harm (<a href="#S4.1">4.1</a>,<a href="#S5.1"> 5.1</a>,<a href="#S8.1"> 8.1</a>).</span></li>
<li><span class="Bold">Females of reproductive potential: exclude pregnancy before start of treatment, monthly during treatment, and 1 month after stopping treatment. Prevent pregnancy during treatment and for one month after treatment by using acceptable methods of contraception (<a href="#S2.2">2.2</a>,<a href="#S8.6"> 8.6</a>).</span></li>
<li><span class="Bold">For all female patients, OPSUMIT is available only through a restricted program called the OPSUMIT Risk Evaluation and Mitigation Strategy (REMS) (<a href="#S5.2">5.2</a>).</span></li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING:  EMBRYO-FETAL TOXICITY</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning</span></h1>
<ul class="Disc">
<li><span class="Bold">Do not administer OPSUMIT to a pregnant female because it may cause fetal harm (<a href="#S4.1">4.1</a>,<a href="#S5.1"> 5.1</a>,<a href="#S8.1"> 8.1</a>).</span></li>
<li><span class="Bold">Females of reproductive potential: exclude pregnancy before start of treatment, monthly during treatment, and 1 month after stopping treatment. Prevent pregnancy during treatment and for one month after treatment by using acceptable methods of contraception (<a href="#S2.2">2.2</a>,<a href="#S8.6"> 8.6</a>).</span></li>
<li><span class="Bold">For all female patients, OPSUMIT is available only through a restricted program called the OPSUMIT Risk Evaluation and Mitigation Strategy (REMS) (<a href="#S5.2">5.2</a>).</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span> (PAH, WHO Group I) to delay disease progression. Disease progression included: <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). OPSUMIT also reduced hospitalization for PAH (<a href="#S1.1">1.1</a>). </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc"><li>10 mg once daily. Doses higher than 10 mg once daily have not been studied in patients with PAH and are not recommended (<a href="#S2.1">2.1</a>).</li></ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Tablet: 10 mg (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>Pregnancy (<a href="#S4.1">4.1</a>)</li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Other ERAs cause hepatotoxicity and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>. Obtain baseline liver enzymes and monitor as clinically indicated (<a href="#S5.3">5.3</a>).</li>
<li>Decreases in hemoglobin (<a href="#S5.4">5.4</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span> in patients with pulmonary veno-occlusive disease. If confirmed, discontinue treatment (<a href="#S5.5">5.5</a>).</li>
<li>Decreases in sperm count have been observed in patients taking ERAs (<a href="#S5.6">5.6</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (more frequent than placebo by ≥3%) are <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> (<a href="#S6.1">6.1</a>). </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Actelion at 1-866-228-3546 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta">Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT (<a href="#S7.1">7.1</a>,<a href="#S12.3"> 12.3</a>). </p>
<p class="Highlighta">Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT (<a href="#S7.2">7.2</a>,<a href="#S12.3"> 12.3</a>). </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Nursing mothers: discontinue OPSUMIT or breastfeeding (<a href="#S8.3">8.3</a>). </p></div>
<div><div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
</div>
</div>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 4/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING:  EMBRYO-FETAL TOXICITY</span></a></h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 	<span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Pulmonary Arterial Hypertension</span></a></h2>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Recommended Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Pregnancy Testing in Females of Reproductive Potential</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1	Pregnancy</a></h2>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Embryo-fetal Toxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	OPSUMIT REMS Program</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	 Hepatotoxicity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Hemoglobin Decrease</a></h2>
<h2><a href="#section-5.5" class="toc">5.5	<span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary Edema</span> with Pulmonary Veno-occlusive Disease (PVOD)</a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Decreased Sperm Counts</a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trial Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Strong CYP3A4 Inducers</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Strong CYP3A4 Inhibitors</a></h2>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5	Geriatric use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	Females and Males of Reproductive Potential</a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11	DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2	Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2	Animal Toxicology</a></h2>
<h1><a href="#section-13" class="toc">14	CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	<span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Pulmonary Arterial Hypertension</span></a></h2>
<h1><a href="#section-14" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING:  EMBRYO-FETAL TOXICITY</span></h1>
<ul class="Disc">
<li>
<span class="Bold">Do not administer OPSUMIT to a pregnant female because it may cause fetal harm </span><span class="Bold Italics">[see<a href="#S4.1"> Contraindications (4.1)</a>,<a href="#S5.1"> Warnings and Precautions (5.1)</a>,<a href="#S8.1"> Use in Specific Populations (8.1)</a>]</span><span class="Bold">.</span>
</li>
<li>
<span class="Bold">Females of reproductive potential: Exclude pregnancy before the start of treatment, monthly during treatment, and 1 month after stopping treatment. Prevent pregnancy during treatment and for one month after stopping treatment by using acceptable methods of contraception </span><span class="Bold Italics">[see<a href="#S8.6"> Use in Special Populations (8.6)</a>]</span><span class="Bold">.</span>
</li>
<li>
<span class="Bold">For all female patients, OPSUMIT is available only through a restricted program called the OPSUMIT Risk Evaluation and Mitigation Strategy (REMS) </span><span class="Bold Italics">[see<a href="#S5.2"> Warnings and Precautions (5.2)</a>]</span><span class="Bold">.</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 	<span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Pulmonary Arterial Hypertension</span></h2>
<p class="First">OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span> (PAH, WHO Group I) to delay disease progression. Disease progression included: <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). OPSUMIT also reduced hospitalization for PAH.</p>
<p>Effectiveness was established in a long-term study in PAH patients with predominantly WHO Functional Class II-III symptoms treated for an average of 2 years. Patients were treated with OPSUMIT monotherapy or in combination with phosphodiesterase-5 inhibitors or inhaled prostanoids. Patients had idiopathic and heritable PAH (57%), PAH caused by <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span> (31%), and PAH caused by congenital heart disease with repaired shunts (8%)<span class="Italics"> [see<a href="#S14.1"> Clinical Studies (14.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Recommended Dosage</h2>
<p class="First">The recommended dosage of OPSUMIT is 10 mg once daily for oral administration. Doses higher than 10 mg once daily have not been studied in patients with PAH and are not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Pregnancy Testing in Females of Reproductive Potential</h2>
<p class="First">Initiate treatment with OPSUMIT in females of reproductive potential only after a <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span>. Obtain monthly pregnancy test during treatment <span class="Italics">[see<a href="#S8.6"> Use in Specific Populations (8.6)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Tablets: 10 mg, bi-convex film-coated, round, white, and debossed with "10" on one side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1	Pregnancy</h2>
<p class="First">OPSUMIT may cause fetal harm when administered to a pregnant woman. OPSUMIT is contraindicated in females who are pregnant. OPSUMIT was consistently shown to have teratogenic effects when administered to animals. If OPSUMIT is used during pregnancy, apprise the patient of the potential hazard to a fetus <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1) </a>and<a href="#S8.1"> Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Embryo-fetal Toxicity</h2>
<p class="First">OPSUMIT may cause fetal harm when administered during pregnancy and is contraindicated for use in females who are pregnant. In females of reproductive potential, exclude pregnancy prior to initiation of therapy, ensure use of acceptable contraceptive methods and obtain monthly pregnancy tests <span class="Italics">[see<a href="#S2.2"> Dosage and Administration (2.2) </a>and<a href="#S8.1"> Use in Specific Populations (8.1</a>,<a href="#S8.6"> 8.6)</a>]</span>.</p>
<p>OPSUMIT is available for females through the OPSUMIT REMS Program, a restricted distribution program <span class="Italics">[see<a href="#S5.2"> Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	OPSUMIT REMS Program</h2>
<p class="First">For all females, OPSUMIT is available only through a restricted program called the OPSUMIT REMS Program, because of the risk of embryo-fetal toxicity <span class="Italics">[see<a href="#S4.1"> Contraindications (4.1)</a>,<a href="#S5.1"> Warnings and Precautions (5.1)</a>, and<a href="#S8.1"> Use in Specific Populations (8.1</a>,<a href="#S8.6"> 8.6)</a>]</span>.</p>
<p>Notable requirements of the OPSUMIT REMS Program include the following:</p>
<ul>
<li>Prescribers must be certified with the program by enrolling and completing training.</li>
<li>All females, regardless of reproductive potential, must enroll in the OPSUMIT REMS Program prior to initiating OPSUMIT. Male patients are not enrolled in the REMS.</li>
<li>Females of reproductive potential must comply with the pregnancy testing and contraception requirements <span class="Italics">[see<a href="#S8.6"> Use in Specific Populations (8.6)</a>]</span>.</li>
<li>Pharmacies must be certified with the program and must only dispense to patients who are authorized to receive OPSUMIT.</li>
</ul>
<p>Further information is available at www.OPSUMITREMS.com or 1-866-228-3546. Information on OPSUMIT certified pharmacies or wholesale distributors is available through Actelion Pathways at 1-866-228-3546.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	 Hepatotoxicity</h2>
<p class="First">Other ERAs have caused elevations of aminotransferases, hepatotoxicity, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>. The incidence of elevated aminotransferases in the study of OPSUMIT in PAH is shown in Table 1.</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1 Incidence of Elevated Aminotransferases in the SERAPHIN Study</span></caption>
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">OPSUMIT 10 mg<br>(N=242)</th>
<th class="Rrule" align="center">Placebo<br>(N=249)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">&gt;3 × ULN</td>
<td class="Rrule" align="center">3.4%</td>
<td class="Rrule" align="center">4.5%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">&gt;8 × ULN</td>
<td class="Rrule" align="center">2.1%</td>
<td class="Rrule" align="center">0.4%</td>
</tr>
</tbody>
</table>
<p>In the placebo-controlled study of OPSUMIT, discontinuations for hepatic adverse events were 3.3% in the OPSUMIT 10 mg group vs. 1.6% for placebo. Obtain liver enzyme tests prior to initiation of OPSUMIT and repeat during treatment as clinically indicated.</p>
<p>Advise patients to report symptoms suggesting hepatic injury (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">right upper quadrant pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, dark urine, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>). If clinically relevant aminotransferase elevations occur, or if elevations are accompanied by an increase in bilirubin &gt;2 × ULN, or by clinical symptoms of hepatotoxicity, discontinue OPSUMIT. Consider re-initiation of OPSUMIT when hepatic enzyme levels normalize in patients who have not experienced clinical symptoms of hepatotoxicity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Hemoglobin Decrease</h2>
<p class="First">Decreases in hemoglobin concentration and hematocrit have occurred following administration of other ERAs and were observed in clinical studies with OPSUMIT. These decreases occurred early and stabilized thereafter. In the placebo-controlled study of OPSUMIT in PAH, OPSUMIT 10 mg caused a mean decrease in hemoglobin from baseline to up to 18 months of about 1.0 g/dL compared to no change in the placebo group. A decrease in hemoglobin to below 10.0 g/dL was reported in 8.7% of the OPSUMIT 10 mg group and in 3.4% of the placebo group. Decreases in hemoglobin seldom require transfusion. Initiation of OPSUMIT is not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. Measure hemoglobin prior to initiation of treatment and repeat during treatment as clinically indicated <span class="Italics">[see<a href="#S6.1"> Adverse Reactions (6.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	<span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary Edema</span> with Pulmonary Veno-occlusive Disease (PVOD)</h2>
<p class="First">Should signs of <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> occur, consider the possibility of associated PVOD. If confirmed, discontinue OPSUMIT.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Decreased Sperm Counts</h2>
<p class="First">Other ERAs have caused adverse effects on spermatogenesis. Counsel men about potential effects on fertility <span class="Italics">[see<a href="#S8.6"> Use in Specific Populations (8.6) </a>and<a href="#S13.1"> Nonclinical Toxicology (13.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<p class="First">Clinically significant adverse reactions that appear in other sections of the labeling include:</p>
<ul>
<li>Embryo-fetal Toxicity <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>
</li>
<li>Hepatotoxicity <span class="Italics">[see<a href="#S5.3"> Warnings and Precautions (5.3)</a>]</span>
</li>
<li>Decrease in Hemoglobin <span class="Italics">[see<a href="#S5.4"> Warnings and Precautions (5.4)</a>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>Safety data for OPSUMIT were obtained primarily from one placebo-controlled clinical study in 742 patients with PAH (SERAPHIN study) <span class="Italics">[see<a href="#S14"> Clinical Studies (14)</a>]</span>. The exposure to OPSUMIT in this trial was up to 3.6 years with a median exposure of about 2 years (N=542 for 1 year; N=429 for 2 years; and N=98 for more than 3 years). The overall incidence of treatment discontinuations because of adverse events was similar across OPSUMIT 10 mg and placebo treatment groups (approximately 11%).</p>
<p>Table 2 presents adverse reactions more frequent on OPSUMIT than on placebo by ≥3%.</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2 Adverse Reactions</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left" valign="bottom"><span class="Italics">Adverse Reaction</span></th>
<th class="Rrule" align="center">OPSUMIT 10 mg<br>(N=242)<br>(%)</th>
<th class="Rrule" align="center">Placebo<br>(N=249)<br>(%)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span></td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">13</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">6</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of OPSUMIT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>)</p>
<p><span class="Italics">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Strong CYP3A4 Inducers</h2>
<p class="First">Strong inducers of CYP3A4 such as rifampin significantly reduce macitentan exposure. Concomitant use of OPSUMIT with strong CYP3A4 inducers should be avoided <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Strong CYP3A4 Inhibitors</h2>
<p class="First">Concomitant use of strong CYP3A4 inhibitors like ketoconazole approximately double macitentan exposure. Many HIV drugs like ritonavir are strong inhibitors of CYP3A4. Avoid concomitant use of OPSUMIT with strong CYP3A4 inhibitors <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>. Use other PAH treatment options when strong CYP3A4 inhibitors are needed as part of HIV treatment <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category X.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Risk Summary</span></p>
<p>OPSUMIT may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy. Macitentan was teratogenic in rabbits and rats at all doses tested. A no-effect dose was not established in either species. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, advise the patient of the potential hazard to a fetus <span class="Italics">[see<a href="#S4.1"> Contraindications (4.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.2"></a><p></p>
<p class="First"><span class="Italics">Animal Data</span></p>
<p>In both rabbits and rats, there were cardiovascular and mandibular arch fusion abnormalities. Administration of macitentan to female rats from late pregnancy through lactation caused reduced pup survival and impairment of the male fertility of the offspring at all dose levels tested.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 	Nursing Mothers</h2>
<p class="First">It is not known whether OPSUMIT is present in human milk. Macitentan and its metabolites were present in the milk of lactating rats. Because many drugs are present in human milk and because of the potential for serious adverse reactions from macitentan in nursing infants, nursing mothers should discontinue nursing or discontinue OPSUMIT.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric use</h2>
<p class="First">The safety and efficacy of OPSUMIT in children have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5	Geriatric use</h2>
<p class="First">Of the total number of subjects in the clinical study of OPSUMIT for PAH, 14% were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	Females and Males of Reproductive Potential</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.1"></a><p></p>
<p class="First"><span class="Underline">Females</span></p>
<p><span class="Italics">Pregnancy Testing</span>: Female patients of reproductive potential must have a <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span> prior to starting treatment with OPSUMIT and monthly pregnancy tests during treatment with OPSUMIT. Advise patients to contact their health care provider if they become pregnant or suspect they may be pregnant. Perform a pregnancy test if pregnancy is suspected for any reason. For <span class="product-label-link" type="condition" conceptid="4094910" conceptname="Pregnancy test positive">positive pregnancy tests</span>, counsel patients on the potential risk to the fetus <span class="Italics">[see<a href="#BOX"> Boxed Warning </a>and<a href="#S2.2"> Dosage and Administration (2.2)</a>]</span>.</p>
<p><span class="Italics">Contraception</span>: Female patients of reproductive potential must use acceptable methods of contraception during treatment with OPSUMIT and for 1 month after treatment with OPSUMIT. Patients may choose one highly effective form of contraception (intrauterine devices (IUD), contraceptive implants or tubal sterilization) or a combination of methods (hormone method with a barrier method or two barrier methods). If a partner's vasectomy is the chosen method of contraception, a hormone or barrier method must be used along with this method. Counsel patients on pregnancy planning and prevention, including emergency contraception, or designate counseling by another healthcare provider trained in contraceptive counseling <span class="Italics">[see<a href="#BOX"> Boxed Warning</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.2"></a><p></p>
<p class="First"><span class="Underline">Males</span></p>
<p><span class="Italics">Testicular effects</span>: Like other endothelin receptor antagonists, OPSUMIT may have an adverse effect on spermatogenesis <span class="Italics">[see<a href="#S5.6"> Warnings and Precautions (5.6) </a>and<a href="#S13.1"> Nonclinical Toxicology (13.1)</a>]</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE</h1>
<p class="First">OPSUMIT has been administered as a single dose of up to and including 600 mg to healthy subjects (60 times the approved dosage). Adverse reactions of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> were observed. In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, standard supportive measures should be taken, as required. Dialysis is unlikely to be effective because macitentan is highly protein-bound.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">OPSUMIT (macitentan) is an endothelin receptor antagonist. The chemical name of macitentan is N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide. It has a molecular formula of C<span class="Sub">19</span>H<span class="Sub">20</span>Br<span class="Sub">2</span>N<span class="Sub">6</span>O<span class="Sub">4</span>S and a molecular weight of 588.27. Macitentan is achiral and has the following structural formula:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1e484a50-55db-4b85-8c57-6cd1b0353abd&amp;name=opsumit-01.jpg"></p>
<p>Macitentan is a crystalline powder that is insoluble in water. In the solid state macitentan is very stable, is not hygroscopic, and is not light sensitive.</p>
<p>OPSUMIT is available as a 10 mg film-coated tablet for once daily oral administration. The tablets include the following inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, polysorbate 80, povidone, and sodium starch glycolate Type A. The tablets are film-coated with a coating material containing polyvinyl alcohol, soya lecithin, talc, titanium dioxide, and xanthan gum.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">Endothelin (ET)-1 and its receptors (ET<span class="Sub">A</span> and ET<span class="Sub">B</span>) mediate a variety of deleterious effects, such as <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>, proliferation, <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>, and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. In disease conditions such as PAH, the local ET system is upregulated and is involved in vascular <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span> and in organ damage.</p>
<p>Macitentan is an endothelin receptor antagonist that prevents the binding of ET-1 to both ET<span class="Sub">A</span> and ET<span class="Sub">B</span> receptors. Macitentan displays high affinity and sustained occupancy of the ET receptors in human pulmonary arterial smooth muscle cells. One of the metabolites of macitentan is also pharmacologically active at the ET receptors and is estimated to be about 20% as potent as the parent drug <span class="Italics">in vitro</span>.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2	Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Italics">Pulmonary Hemodynamics</span>: The clinical efficacy study in patients with <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span> assessed hemodynamic parameters in a subset of patients after 6 months of treatment. Patients treated with OPSUMIT 10 mg (N=57) achieved a median reduction of 37% (95% CI 22-49) in pulmonary <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and an increase of 0.6 L/min/m<span class="Sup">2</span> (95% CI 0.3-0.9) in <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> compared to placebo (N=67).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Italics">Cardiac Electrophysiology</span>: In a randomized, placebo-controlled four-way crossover study with a positive control in healthy subjects, repeated doses of macitentan 10 and 30 mg (3 times the recommended dosage) had no significant effect on the QTc interval.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of macitentan and its active metabolite have been studied primarily in healthy subjects. The pharmacokinetics of macitentan are dose proportional over a range from 1 mg to 30 mg after once daily administration.</p>
<p>A cross study comparison shows that the exposures to macitentan and its active metabolite in patients with PAH are similar to those observed in healthy subjects.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption and Distribution</span></p>
<p>The maximum plasma concentration of macitentan is achieved about 8 hours after oral administration. The absolute bioavailability after oral administration is not known. In a study in healthy subjects, the exposure to macitentan and its active metabolite were unchanged after a high fat breakfast. Macitentan may therefore be taken with or without food.</p>
<p>Macitentan and its active metabolite are highly bound to plasma proteins (&gt;99%), primarily to albumin and to a lesser extent to alpha-1-acid glycoprotein. The apparent volumes of distribution (Vss/F) of macitentan and its active metabolite were about 50 L and 40 L respectively in healthy subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Metabolism and Elimination</span></p>
<p>Following oral administration, the apparent elimination half-lives of macitentan and its active metabolite are approximately 16 hours and 48 hours, respectively. Macitentan is metabolized primarily by oxidative depropylation of the sulfamide to form the pharmacologically active metabolite. This reaction is dependent on the cytochrome P450 (CYP) system, mainly CYP3A4 with a minor contribution of CYP2C19. At steady state in PAH patients, the systemic exposure to the active metabolite is 3-times the exposure to macitentan and is expected to contribute approximately 40% of the total pharmacologic activity. In a study in healthy subjects with radiolabeled macitentan, approximately 50% of radioactive drug material was eliminated in urine but none was in the form of unchanged drug or the active metabolite. About 24% of the radioactive drug material was recovered from feces.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline">Special Populations</span></p>
<p>There are no clinically relevant effects of age, sex, or race on the pharmacokinetics of macitentan and its active metabolite.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span></span>: Exposure to macitentan and its active metabolite in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl 15-29 mL/min) compared to healthy subjects was increased by 30% and 60%, respectively. This increase is not considered clinically relevant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span></span>: Exposure to macitentan was decreased by 21%, 34%, and 6% and exposure to the active metabolite was decreased by 20%, 25%, and 25% in subjects with mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class A, B, and C), respectively. This decrease is not considered clinically relevant.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline">Drug Interactions</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.1"></a><p></p>
<p class="First"><span class="Italics Underline">In vitro studies</span></p>
<p>At plasma levels obtained with dosing at 10 mg once daily, macitentan has no relevant inhibitory or inducing effects on CYP enzymes, and is neither a substrate nor an inhibitor of the multi-<span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> protein (P-gp, MDR-1). Macitentan and its active metabolite are neither substrates nor inhibitors of the organic anion transporting polypeptides (OATP1B1 and OATP1B3) and do not significantly interact with proteins involved in hepatic bile salt transport, i.e., the bile salt export pump (BSEP) and the sodium-dependent taurocholate co-transporting polypeptide (NTCP).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.2"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">In vivo studies</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.2.1"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Effect of other drugs on macitentan: </span></span>The effect of other drugs on macitentan and its active metabolite are studied in healthy subjects and are shown in Figure 1 below.</p>
<p><span class="Bold">Figure 1</span></p>
<p><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1e484a50-55db-4b85-8c57-6cd1b0353abd&amp;name=opsumit-02.jpg"></p>
<p>Effects of other strong CYP3A4 inhibitors such as ritonavir on macitentan were not studied, but are likely to result in an increase in macitentan exposure at steady state similar to that seen with ketoconazole <span class="Italics">[see<a href="#S7.2"> Drug Interactions (7.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.2.2"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Effect of macitentan on other drugs </span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.2.2.1"></a><p></p>
<p class="First"><span class="Italics">Warfarin:</span> Macitentan once daily dosing did not alter the exposure to R- and S-warfarin or their effect on international normalized ratio (INR).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4.2.2.2"></a><p></p>
<p class="First"><span class="Italics">Sildenafil:</span> At steady-state, the exposure to sildenafil 20 mg t.i.d. increased by 15% during concomitant administration of macitentan 10 mg once daily. This change is not considered clinically relevant.</p>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Italics">Carcinogenesis</span>: Carcinogenicity studies of 2 years' duration did not reveal any carcinogenic potential at exposures 75-fold and 140-fold the human exposure (based on AUC) in male and female mice, respectively, and 8.3- and 42-fold in male and female rats, respectively.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Italics">Mutagenesis</span>: Macitentan was not genotoxic in a standard battery of <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> assays that included a bacterial reverse mutation assay, an assay for gene mutations in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells, a chromosome aberration test in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and an <span class="Italics">in vivo</span> micronucleus test in rats.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1.3"></a><p></p>
<p class="First"><span class="Italics">Impairment of Fertility</span>: Treatment of juvenile rats from postnatal Day 4 to Day 114 led to reduced body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and testicular tubular <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> at exposures 7-fold the human exposure. Fertility was not affected.</p>
<p>Reversible testicular tubular dilatation was observed in chronic toxicity studies at exposures greater than 7-fold and 23-fold the human exposure in rats and dogs, respectively. After 2 years of treatment, tubular <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> was seen in rats at 4-fold the human exposure. Macitentan did not affect male or female fertility at exposures ranging from 19- to 44-fold the human exposure, respectively, and had no effect on sperm count, motility, and morphology in male rats. No testicular findings were noted in mice after treatment up to 2 years.</p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2	Animal Toxicology</h2>
<p class="First">In dogs, macitentan decreased blood pressure at exposures similar to the therapeutic human exposure. Intimal thickening of coronary arteries was observed at 17-fold the human exposure after 4 to 39 weeks of treatment. Due to the species-specific sensitivity and the safety margin, this finding is considered not relevant for humans.</p>
<p>There were no adverse liver findings in long-term studies conducted in mice, rats, and dogs at exposures of 12- to 116-fold the human exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14	CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	<span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Pulmonary Arterial Hypertension</span></h2>
<p class="First">The effect of macitentan on progression of PAH was demonstrated in a multi-center, long-term (average duration of exposure approximately 2 years), placebo-controlled study in 742 patients with symptomatic [WHO functional class (FC) II-IV] PAH who were randomized to placebo (n=250), 3 mg macitentan (n=250), or 10 mg macitentan (n=242) once daily.</p>
<p>The primary study endpoint was time to the first occurrence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, a significant morbidity event, defined as atrial septostomy, lung transplantation, initiation of IV or subcutaneous (SC) prostanoids, or "other worsening of PAH" during double-blind treatment plus 7 days. Other worsening was defined as all of the following: 1) a sustained ≥15% decrease from baseline in 6 minute walk distance (6MWD), 2) worsening of PAH symptoms (worsening of WHO FC), and 3) need for additional treatment for PAH. All of these other worsening events were confirmed by an independent adjudication committee, blinded to treatment allocation. A critical secondary endpoint was time to PAH <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or PAH hospitalization.</p>
<p>The mean patient age was 46 years (14% were age 65 or above). Most patients were white (55%) or Asian (29%) and female (77%). Approximately 52%, 46%, and 2% of patients were in WHO FC II, III, and IV, respectively.</p>
<p>Idiopathic or heritable PAH was the most common etiology in the study population (57%) followed by PAH caused by <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span> (31%), PAH caused by congenital heart disease with repaired shunts (8%), and PAH caused by other etiologies [drugs and toxins (3%) and HIV (1%)].</p>
<p>At baseline, the majority of enrolled patients (64%) were being treated with a stable dose of specific therapy for PAH, either oral phosphodiesterase inhibitors (61%) and/or inhaled/oral prostanoids (6%).</p>
<p>Study results are described for the placebo and OPSUMIT 10 mg groups. The median treatment durations were 101 and 118 weeks in the placebo and OPSUMIT 10 mg groups, respectively, up to a maximum of 188 weeks.</p>
<p>Treatment with OPSUMIT 10 mg resulted in a 45% reduction (HR 0.55, 97.5% CI 0.39-0.76; logrank p&lt;0.0001) in the occurrence of the primary endpoint up to end of double-blind treatment compared to placebo (Table 3 and Figure 2). The beneficial effect of OPSUMIT 10 mg was primarily attributable to a reduction in clinical worsening events (deterioration in 6MWD and worsening of PAH symptoms and need for additional PAH treatment).</p>
<p><span class="Bold">Figure 2 Kaplan-Meier Estimates of the Occurrence of the Primary Endpoint Event in the SERAPHIN Study</span></p>
<p><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1e484a50-55db-4b85-8c57-6cd1b0353abd&amp;name=opsumit-03.jpg"></p>
<a name="table3"></a><table width="75%">
<caption><span>Table 3 Summary of Primary Endpoint Events</span></caption>
<col align="left" valign="top" width="60%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Placebo<br>N=250<br>n (%)</th>
<th class="Rrule" align="center">OPSUMIT 10 mg<br>N=242<br>n (%)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>No patients experienced an event of lung transplantation or atrial septostomy in the placebo or OPSUMIT 10 mg treatment groups.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Patients with a primary endpoint event<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Rrule" align="center">116 (46.4)</td>
<td class="Rrule" align="center">76 (31.4)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Component as first event</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Worsening PAH</td>
<td class="Rrule" align="center">93 (37.2)</td>
<td class="Rrule" align="center">59 (24.4)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td class="Rrule" align="center">17 (6.8)</td>
<td class="Rrule" align="center">16 (6.6)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  IV/SC prostanoid </td>
<td class="Rrule" align="center">6 (2.4)</td>
<td class="Rrule" align="center">1 (0.4)</td>
</tr>
</tbody>
</table>
<p>Subgroup analyses were performed to examine their influence on outcome as shown in Figure 3. Consistent efficacy of OPSUMIT 10 mg on the primary endpoint was seen across subgroups of age, sex, race, etiology, by monotherapy or in combination with another PAH therapy, baseline 6MWD, and baseline WHO FC.</p>
<p><span class="Bold">Figure 3 Subgroup Analysis of the SERAPHIN Study</span></p>
<p><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1e484a50-55db-4b85-8c57-6cd1b0353abd&amp;name=opsumit-04.jpg"></p>
<p>Eo = Number of events OPSUMIT 10 mg; No = Number of patients randomized to OPSUMIT 10 mg<br>Ep = Number of events placebo; Np = Number of patients randomized to placebo</p>
<p>PAH related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or hospitalization for PAH was assessed as a secondary endpoint. The risk of PAH related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or hospitalization for PAH was reduced by 50% in patients receiving OPSUMIT 10 mg compared to placebo (HR 0.50, 97.5% CI 0.34-0.75; logrank p&lt;0.0001) (Table 4 and Figure 4).</p>
<p><span class="Bold">Figure 4 Kaplan-Meier Estimates of the Occurrence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to PAH or Hospitalization for PAH in SERAPHIN</span></p>
<p><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1e484a50-55db-4b85-8c57-6cd1b0353abd&amp;name=opsumit-05.jpg"></p>
<a name="table4"></a><table width="75%">
<caption><span>Table 4 Summary of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to PAH and Hospitalization due to PAH</span></caption>
<col align="left" valign="top" width="60%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Placebo<br>(N=250)<br>n (%)</th>
<th class="Rrule" align="center">OPSUMIT 10 mg<br>(N=242)<br>n (%)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to PAH or hospitalization for PAH</td>
<td class="Rrule" align="center">84 (33.6)</td>
<td class="Rrule" align="center">50 (20.7)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Component as first event</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to PAH</td>
<td class="Rrule" align="center">5 (2.0)</td>
<td class="Rrule" align="center">5 (2.1)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Hospitalization for PAH</td>
<td class="Rrule" align="center">79 (31.6)</td>
<td class="Rrule" align="center">45 (18.6)</td>
</tr>
</tbody>
</table>
<p>Treatment with OPSUMIT 10 mg resulted in a placebo-corrected mean increase in 6MWD of 22 meters at Month 6 (97.5% CI 3-41; p=0.0078), with significant improvement in 6MWD by Month 3. 6MWD increased more in patients with worse baseline WHO Functional Class (37 meters and 12 meters placebo-corrected mean increase in WHO FC III/IV and FC I/II, respectively). The increase in 6MWD achieved with OPSUMIT was maintained for the duration of the study.</p>
<p>Treatment with OPSUMIT 10 mg led to an improvement of at least one WHO Functional Class at Month 6 in 22% of patients compared to 13% of patients treated with placebo.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">OPSUMIT tablets are 10 mg white, film-coated, bi-convex debossed with "10" on one side and supplied as follows:</p>
<p>15 count /PVC/ PE/PVDC aluminum foil <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> in carton (NDC 66215-501-15)</p>
<p>30 count white high-density polyethylene bottle in carton (NDC 66215-501-30)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Store at 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F and 86°F). [See USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<p class="First">See<a href="#MG"> FDA-approved patient labeling (Medication Guide)</a>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<p class="First"><span class="Underline">Embryo-Fetal Toxicity</span></p>
<p>Instruct patients on the risk of fetal harm when OPSUMIT is used in pregnancy <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1) </a>and<a href="#S8.1"> Use in Specific Populations (8.1)</a>]</span>. Instruct females of reproductive potential to use effective contraception and to contact her physician if they suspect they may be pregnant. Female patients must enroll in the OPSUMIT REMS program.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.2"></a><p></p>
<p class="First"><span class="Underline">OPSUMIT REMS Program</span></p>
<p>For female patients, OPSUMIT is available only through a restricted program called the OPSUMIT REMS Program <span class="Italics">[see<a href="#S5.2"> Warnings and Precautions (5.2)</a>]</span>. Male patients are not enrolled in the OPSUMIT REMS.</p>
<p>Inform female patients (and their guardians, if applicable) of the following notable requirements.</p>
<ul>
<li>Female patients must sign an enrollment form.</li>
<li>Female patients of reproductive potential must comply with the pregnancy testing and contraception requirements <span class="Italics">[see<a href="#S8.6"> Use in Specific Populations (8.6)</a>]</span>.</li>
</ul>
<p>Educate and counsel females of reproductive potential on the use of emergency contraception in the event of unprotected sex or contraceptive failure.</p>
<p>Advise pre-pubertal females to report any changes in their reproductive status immediately to her prescriber.</p>
<p>Review the Medication Guide and REMS educational materials with female patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.3"></a><p></p>
<p class="First"><span class="Underline">Decrease in Hemoglobin</span></p>
<p>Advise patients on the importance of hemoglobin testing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.4"></a><p></p>
<p class="First"><span class="Underline">Hepatotoxicity</span></p>
<p>Some members of this pharmacological class are hepatotoxic. Educate patients on signs of hepatotoxicity. Advise patients that they should contact their doctor if they have unexplained <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">right upper quadrant pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, dark urine, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.5"></a><p></p>
<p class="First"><span class="Underline">Administration</span></p>
<p>Patients should be advised not to split, crush, or chew tablets.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Manufactured for:<br>Actelion Pharmaceuticals US, Inc.<br>5000 Shoreline Court, Ste. 200<br>South San Francisco, CA 94080, USA</p>
<p>© 2015 Actelion Pharmaceuticals US, Inc. All rights reserved.</p>
<p>ACT20150512</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="MG"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">OPSUMIT<span class="Sup">®</span> (OP-sum-it)<br>(macitentan)<br>tablets</span></p>
<p>Read this Medication Guide for Opsumit before you start taking Opsumit and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your healthcare provider about your medical condition or your treatment.</p>
<p><a name="mostimportant"></a><span class="Bold">What is the most important information I should know about Opsumit?</span></p>
<ul class="Disc"><li>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>.<br>Opsumit can cause serious <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> if taken during pregnancy. </span><ul class="Square">
<li><span class="Bold">Females must not be pregnant when they start taking Opsumit or become pregnant during treatment with Opsumit.</span></li>
<li>Females who are able to get pregnant must have a <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span> before beginning treatment with Opsumit, each month during treatment with Opsumit and 1 month after stopping Opsumit. Talk to your healthcare provider about your menstrual cycle. Your healthcare provider will decide when to do the tests, and order the tests for you depending on your menstrual cycle.<ul class="Circle">
<li>Females who <span class="Underline">are able</span> to get pregnant are females who:<ul>
<li>Have entered puberty, even if they have not started their period, <span class="Bold">and</span>
</li>
<li>Have a uterus, <span class="Bold">and</span>
</li>
<li>Have not gone through <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (have not had a period for at least 12 months for natural reasons, or who have had their ovaries removed)</li>
</ul>
</li>
<li>Females who <span class="Underline">are not able</span> to get pregnant are females who:<ul>
<li>Have not yet entered puberty, <span class="Bold">or</span>
</li>
<li>Do not have a uterus, <span class="Bold">or</span>
</li>
<li>Have gone through <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (have not had a period for at least 12 months for natural reasons, or who have had their ovaries removed)</li>
</ul>
</li>
</ul>
</li>
</ul>
<span class="Bold">Females who are able to get pregnant must use two acceptable forms of birth control during treatment with Opsumit, and for one month after stopping Opsumit because the medicine may still be in the body. </span><ul class="Square">
<li>If you have had a tubal sterilization, have a progesterone implant, or have an IUD (intrauterine device), these methods can be used alone and no other form of birth control is needed.</li>
<li>Talk with your healthcare provider or gynecologist (a doctor who specializes in female reproduction) to find out about options for acceptable birth control that you may use to prevent pregnancy during treatment with Opsumit.</li>
<li>If you decide that you want to change the form of birth control that you use, talk with your healthcare provider or gynecologist to be sure that you choose another acceptable form of birth control.</li>
</ul>
<span class="Bold">See the<a href="#chart"> chart </a>below for Acceptable Birth Control Options during treatment with Opsumit.</span><br><div class="Figure">
<a name="chart"></a><img alt="Chart" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1e484a50-55db-4b85-8c57-6cd1b0353abd&amp;name=opsumit-06.jpg">
</div>
<ul class="Square">
<li><span class="Bold">Do not have unprotected sex. Talk to your healthcare provider or pharmacist right away if you have unprotected sex or if you think your birth control has failed. Your healthcare provider may talk with you about using emergency birth control. </span></li>
<li><span class="Bold">Tell your healthcare provider right away if you miss a menstrual period or think you may be pregnant for any reason.</span></li>
</ul>If you are the parent or caregiver of a female child who started taking Opsumit before reaching puberty, you should check your child regularly to see if she is developing signs of puberty. Tell your healthcare provider right away if you notice that she is developing breast buds or any pubic hair. Your healthcare provider should decide if your child has reached puberty. <span class="Bold">Your child may reach puberty before having her first menstrual period. </span><br>Females can only receive Opsumit through a restricted program called the Opsumit Risk Evaluation and Mitigation Strategy (REMS) Program. If you are a female who can get pregnant, you must talk to your healthcare provider, understand the benefits and risks of Opsumit, and agree to all of the instructions in the Opsumit REMS Program.<br>Males can receive Opsumit without taking part in the Opsumit REMS Program.</li></ul>
<p><span class="Bold">What is Opsumit?</span></p>
<ul class="Disc">
<li>Opsumit is a prescription medicine used to treat <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span> (PAH), which is high blood pressure in the arteries of your lungs.</li>
<li>Opsumit can improve your ability to exercise, improve some of your symptoms, and help slow down the progression of your disease. Opsumit can also lower your chance of being hospitalized for PAH.</li>
<li>It is not known if Opsumit is safe and effective in children.</li>
</ul>
<p><span class="Bold">Who should not take Opsumit?</span></p>
<p><span class="Bold">Do not take Opsumit if you are pregnant, plan to become pregnant, or become pregnant during treatment with Opsumit. Opsumit can cause serious <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span></span> (see the Medication Guide section above called "<a href="#mostimportant">What is the most important information I should know about Opsumit</a>?").</p>
<p><span class="Bold">Tell your healthcare provider about all your medical conditions and all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.</span> Opsumit and other medicines may affect each other causing side effects. Do not start any new medicine until you check with your healthcare provider.</p>
<p>Especially tell your healthcare provider if you take an HIV medicine.</p>
<p><span class="Bold">How should I take Opsumit?</span></p>
<p>Opsumit will be mailed to you by a specialty pharmacy. Your healthcare provider will give you complete details.</p>
<ul class="Disc">
<li>Take Opsumit exactly as your healthcare provider tells you to take it. Do not stop taking Opsumit unless your healthcare provider tells you.</li>
<li>You can take Opsumit with or without food.</li>
<li>Do not split, crush, or chew Opsumit tablets.</li>
<li>If you take too much Opsumit, call your healthcare provider or go to the nearest hospital emergency room right away.</li>
<li>If you miss a dose of Opsumit, take it as soon as you remember that day. Take the next dose at your regular time. Do not take 2 doses at the same time to make up for a missed dose.</li>
</ul>
<p><span class="Bold">What should I avoid while taking Opsumit?</span></p>
<ul class="Disc">
<li>
<span class="Bold">Do not get pregnant while taking Opsumit. </span>See the serious <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> section of the Medication Guide above called "<a href="#mostimportant">What is the most important information I should know about Opsumit</a>?" If you miss a menstrual period, or think you might be pregnant, call your healthcare provider right away.</li>
<li>
<span class="Bold">It is not known if Opsumit passes into your breastmilk. You should not breastfeed if you take Opsumit.</span> Talk to your healthcare provider about the best way to feed your baby if you take Opsumit.</li>
</ul>
<p><span class="Bold">What are the possible side effects of Opsumit?</span></p>
<p><span class="Bold">Opsumit can cause serious side effects, including:</span></p>
<ul class="Disc">
<li>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. </span>See "<a href="#mostimportant">What is the most important information I should know about Opsumit</a>?"</li>
<li>Some medicines that are like Opsumit can cause liver problems. Your healthcare provider should do blood tests to check your liver before you start taking Opsumit. Tell your healthcare provider if you have any of the following symptoms of liver problems while taking Opsumit.<table class="Noautorules" width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the upper right stomach</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li>loss of appetite</li>
</ul></td>
<td align="left"><ul class="Disc">
<li>yellowing of your skin or whites of your eyes</li>
<li>dark urine</li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
</ul></td>
</tr></tbody>
</table>
</li>
<li>
<span class="Bold">Low red blood cell levels (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>) can occur with Opsumit treatment, usually during the first weeks after starting therapy. In some cases a blood transfusion may be needed, but this is not common. </span>Your healthcare provider will do blood tests to check your red blood cells before starting Opsumit. Your healthcare provider may also need to do these tests during treatment with Opsumit.</li>
<li>
<span class="Bold">Sperm count reduction. </span>Reduced sperm counts have been observed in some men taking a medicine similar to Opsumit, an effect which might impair their ability to father a child. Tell your healthcare provider if remaining fertile is important to you.</li>
</ul>
<p>The most common side effects of Opsumit are:</p>
<ul class="Disc">
<li>Stuffy nose or <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></li>
<li>Irritation of the airways (<span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li>Flu</li>
<li><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Opsumit. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store Opsumit?</span></p>
<ul>
<li>Store Opsumit tablets at room temperature between 68°F and 77°F (20°C and 25°C).</li>
<li><span class="Bold">Keep Opsumit and all medicines out of the reach of children.</span></li>
</ul>
<p><span class="Bold">General information about Opsumit</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Opsumit for a condition for which it was not prescribed. Do not give Opsumit to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about Opsumit. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about Opsumit that is written for health professionals. For more information, call 1-866-228-3546, or visit www.OPSUMIT.com.</p>
<p><span class="Bold">What are the ingredients in Opsumit?</span></p>
<p>Active ingredient: macitentan</p>
<p>Inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, polysorbate 80, povidone, and sodium starch glycolate Type A. The tablets are film-coated with a coating material containing polyvinyl alcohol, soya lecithin, talc, titanium dioxide, and xanthan gum.</p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration</span>.</p>
<p>Manufactured for:<br>Actelion Pharmaceuticals US, Inc.<br>5000 Shoreline Court, Ste. 200<br>South San Francisco, CA 94080, USA<br>Issued: April 2015<br>ACT20150512</p>
<p>© 2015 Actelion Pharmaceuticals US, Inc. All rights reserved.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Carton</h1>
<p class="First">NDC<span class="Bold"> 66215-501-30</span><br>30 tablets</p>
<p><span class="Bold">Opsumit<span class="Sub">®</span></span><br>macitentan tablets</p>
<p><span class="Bold">10mg</span></p>
<p>Rx only</p>
<p><span class="Bold">Dispense the<br>accompanying<br>Medication Guide<br>to each patient</span></p>
<p><span class="Bold">ACTELION</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1e484a50-55db-4b85-8c57-6cd1b0353abd&amp;name=opsumit-07.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OPSUMIT 		
					</strong><br><span class="contentTableReg">macitentan tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66215-501</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>macitentan</strong> (macitentan) </td>
<td class="formItem">macitentan</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Lactose monohydrate</strong></td>
<td class="formItem">38.86 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Cellulose, Microcrystalline</strong></td>
<td class="formItem">15.75 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium starch glycolate type A potato</strong></td>
<td class="formItem">2.8 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Povidones</strong></td>
<td class="formItem">2.1 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Magnesium stearate</strong></td>
<td class="formItem">0.35 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Polysorbate 80</strong></td>
<td class="formItem">0.14 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">10</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66215-501-30</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:66215-501-15</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">15  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204410</td>
<td class="formItem">10/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Actelion Pharmaceuticals US, Inc.
							(002641228)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Actelion Pharmaceuticals Ltd. (480007868)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Italia S.p.A</td>
<td class="formItem"></td>
<td class="formItem">338336589</td>
<td class="formItem">MANUFACTURE(66215-501)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Lonza Ltd.</td>
<td class="formItem"></td>
<td class="formItem">480007517</td>
<td class="formItem">MANUFACTURE(66215-501)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a5b4a23d-735c-40a0-ba90-ab51eaa34656</div>
<div>Set id: 1e484a50-55db-4b85-8c57-6cd1b0353abd</div>
<div>Version: 6</div>
<div>Effective Time: 20150514</div>
</div>
</div> <div class="DistributorName">Actelion Pharmaceuticals US, Inc.</div></p>
</body></html>
